BACKGROUND: Randomized trials have shown that the transplantation of filgrastim-mobilized peripheral-blood stem cells from HLA-identical siblings accelerates engraftment but increases the risks of acute and chronic graft-versus-host disease (GVHD), as compared with the transplantation of bone marrow. Some studies have also shown that peripheral-blood stem cells are associated with a decreased rate of relapse and improved survival among recipients with high-risk leukemia. METHODS: We conducted a phase 3, multicenter, randomized trial of transplantation of peripheral-blood stem cells versus bone marrow from unrelated donors to compare 2-year survival probabilities with the use of an intention-to-treat analysis. Between March 2004 and September 2009, we enrolled 551 patients at 48 centers. Patients were randomly assigned in a 1:1 ratio to peripheral-blood stem-cell or bone marrow transplantation, stratified according to transplantation center and disease risk. The median follow-up of surviving patients was 36 months (interquartile range, 30 to 37). RESULTS: The overall survival rate at 2 years in the peripheral-blood group was 51% (95% confidence interval [CI], 45 to 57), as compared with 46% (95% CI, 40 to 52) in the bone marrow group (P=0.29), with an absolute difference of 5 percentage points (95% CI, -3 to 14). The overall incidence of graft failure in the peripheral-blood group was 3% (95% CI, 1 to 5), versus 9% (95% CI, 6 to 13) in the bone marrow group (P=0.002). The incidence of chronic GVHD at 2 years in the peripheral-blood group was 53% (95% CI, 45 to 61), as compared with 41% (95% CI, 34 to 48) in the bone marrow group (P=0.01). There were no significant between-group differences in the incidence of acute GVHD or relapse. CONCLUSIONS: We did not detect significant survival differences between peripheral-blood stem-cell and bone marrow transplantation from unrelated donors. Exploratory analyses of secondary end points indicated that peripheral-blood stem cells may reduce the risk of graft failure, whereas bone marrow may reduce the risk of chronic GVHD. (Funded by the National Heart, Lung, and Blood Institute-National Cancer Institute and others; ClinicalTrials.gov number, NCT00075816.).
RCT Entities:
BACKGROUND: Randomized trials have shown that the transplantation of filgrastim-mobilized peripheral-blood stem cells from HLA-identical siblings accelerates engraftment but increases the risks of acute and chronic graft-versus-host disease (GVHD), as compared with the transplantation of bone marrow. Some studies have also shown that peripheral-blood stem cells are associated with a decreased rate of relapse and improved survival among recipients with high-risk leukemia. METHODS: We conducted a phase 3, multicenter, randomized trial of transplantation of peripheral-blood stem cells versus bone marrow from unrelated donors to compare 2-year survival probabilities with the use of an intention-to-treat analysis. Between March 2004 and September 2009, we enrolled 551 patients at 48 centers. Patients were randomly assigned in a 1:1 ratio to peripheral-blood stem-cell or bone marrow transplantation, stratified according to transplantation center and disease risk. The median follow-up of surviving patients was 36 months (interquartile range, 30 to 37). RESULTS: The overall survival rate at 2 years in the peripheral-blood group was 51% (95% confidence interval [CI], 45 to 57), as compared with 46% (95% CI, 40 to 52) in the bone marrow group (P=0.29), with an absolute difference of 5 percentage points (95% CI, -3 to 14). The overall incidence of graft failure in the peripheral-blood group was 3% (95% CI, 1 to 5), versus 9% (95% CI, 6 to 13) in the bone marrow group (P=0.002). The incidence of chronic GVHD at 2 years in the peripheral-blood group was 53% (95% CI, 45 to 61), as compared with 41% (95% CI, 34 to 48) in the bone marrow group (P=0.01). There were no significant between-group differences in the incidence of acute GVHD or relapse. CONCLUSIONS: We did not detect significant survival differences between peripheral-blood stem-cell and bone marrow transplantation from unrelated donors. Exploratory analyses of secondary end points indicated that peripheral-blood stem cells may reduce the risk of graft failure, whereas bone marrow may reduce the risk of chronic GVHD. (Funded by the National Heart, Lung, and Blood Institute-National Cancer Institute and others; ClinicalTrials.gov number, NCT00075816.).
Authors: Stephen Couban; David R Simpson; Michael J Barnett; Christopher Bredeson; Lothar Hubesch; Kang Howson-Jan; Tsiporah B Shore; Irwin R Walker; Peter Browett; Hans A Messner; Tony Panzarella; Jeffrey H Lipton Journal: Blood Date: 2002-09-01 Impact factor: 22.113
Authors: Philippe Guardiola; Volker Runde; Andrea Bacigalupo; Tapani Ruutu; Franco Locatelli; Marc A Boogaerts; Antonio Pagliuca; Jan J Cornelissen; Harry C Schouten; Enric Carreras; Jürgen Finke; Anja van Biezen; Ronald Brand; Dietger Niederwieser; Eliane Gluckman; Theo M de Witte Journal: Blood Date: 2002-06-15 Impact factor: 22.113
Authors: Norbert Schmitz; Meral Beksac; Dirk Hasenclever; Andrea Bacigalupo; Tapani Ruutu; Arnon Nagler; Eliane Gluckman; Nigel Russell; Jane F Apperley; Norbert C Gorin; Jeff Szer; Ken Bradstock; Agnes Buzyn; Peter Clark; Keith Borkett; Alois Gratwohl Journal: Blood Date: 2002-08-01 Impact factor: 22.113
Authors: Mary E D Flowers; Pablo M Parker; Laura J Johnston; Alice V B Matos; Barry Storer; William I Bensinger; Rainer Storb; Frederick R Appelbaum; Stephen J Forman; Karl G Blume; Paul J Martin Journal: Blood Date: 2002-07-15 Impact factor: 22.113
Authors: W I Bensinger; C H Weaver; F R Appelbaum; S Rowley; T Demirer; J Sanders; R Storb; C D Buckner Journal: Blood Date: 1995-03-15 Impact factor: 22.113
Authors: H M Shulman; K M Sullivan; P L Weiden; G B McDonald; G E Striker; G E Sale; R Hackman; M S Tsoi; R Storb; E D Thomas Journal: Am J Med Date: 1980-08 Impact factor: 4.965
Authors: M Y Detrait; S Morisset; R Peffault de Latour; I Yakoub-Agha; R Crocchiolo; R Tabrizi; J-O Bay; P Chevalier; F Barraco; N Raus; S Vigouroux; L Magro; M Mohty; N Milpied; D Blaise; G Socié; M Michallet Journal: Bone Marrow Transplant Date: 2014-11-03 Impact factor: 5.483
Authors: Jo-Anne H Young; Brent R Logan; Juan Wu; John R Wingard; Daniel J Weisdorf; Cathryn Mudrick; Kristin Knust; Mary M Horowitz; Dennis L Confer; Erik R Dubberke; Steven A Pergam; Francisco M Marty; Lynne M Strasfeld; Janice Wes M Brown; Amelia A Langston; Mindy G Schuster; Daniel R Kaul; Stanley I Martin; Claudio Anasetti Journal: Biol Blood Marrow Transplant Date: 2015-09-25 Impact factor: 5.742
Authors: Anthony Stein; Joycelynne Palmer; Ni-Chun Tsai; Monzr M Al Malki; Ibrahim Aldoss; Haris Ali; Ahmed Aribi; Len Farol; Chatchada Karanes; Samer Khaled; An Liu; Margaret O'Donnell; Pablo Parker; Anna Pawlowska; Vinod Pullarkat; Eric Radany; Joseph Rosenthal; Firoozeh Sahebi; Amandeep Salhotra; James F Sanchez; Tim Schultheiss; Ricardo Spielberger; Sandra H Thomas; David Snyder; Ryotaro Nakamura; Guido Marcucci; Stephen J Forman; Jeffrey Wong Journal: Biol Blood Marrow Transplant Date: 2017-01-10 Impact factor: 5.742
Authors: Laëtitia Le Texier; Katie E Lineburg; Benjamin Cao; Cameron McDonald-Hyman; Lucie Leveque-El Mouttie; Jemma Nicholls; Michelle Melino; Blessy C Nalkurthi; Kylie A Alexander; Bianca Teal; Stephen J Blake; Fernando Souza-Fonseca-Guimaraes; Christian R Engwerda; Rachel D Kuns; Steven W Lane; Michele Teng; Charis Teh; Daniel Gray; Andrew D Clouston; Susan K Nilsson; Bruce R Blazar; Geoffrey R Hill; Kelli Pa MacDonald Journal: JCI Insight Date: 2016-09-22
Authors: Hannah Major-Monfried; Anne S Renteria; Attaphol Pawarode; Pavan Reddy; Francis Ayuk; Ernst Holler; Yvonne A Efebera; William J Hogan; Matthias Wölfl; Muna Qayed; Elizabeth O Hexner; Kitsada Wudhikarn; Rainer Ordemann; Rachel Young; Jay Shah; Matthew J Hartwell; Mohammed S Chaudhry; Mina Aziz; Aaron Etra; Gregory A Yanik; Nicolaus Kröger; Daniela Weber; Yi-Bin Chen; Ryotaro Nakamura; Wolf Rösler; Carrie L Kitko; Andrew C Harris; Michael Pulsipher; Ran Reshef; Steven Kowalyk; George Morales; Ivan Torres; Umut Özbek; James L M Ferrara; John E Levine Journal: Blood Date: 2018-03-15 Impact factor: 22.113
Authors: P V O'Donnell; M Eapen; M M Horowitz; B R Logan; A DiGilio; C Brunstein; E J Fuchs; M E D Flowers; R Salit; K Raj; A Pagliuca; K Bradstock; A Granata; L Castagna; S Furst; D Blaise Journal: Bone Marrow Transplant Date: 2016-08-15 Impact factor: 5.483